L
L. Gardner
Researcher at Emory University
Publications - 25
Citations - 564
L. Gardner is an academic researcher from Emory University. The author has contributed to research in topics: Perifosine & Lenalidomide. The author has an hindex of 13, co-authored 23 publications receiving 550 citations.
Papers
More filters
Journal ArticleDOI
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
Paul G. Richardson,Jeff Wolf,Andrzej Jakubowiak,Jeff Zonder,Sagar Lonial,David Irwin,John J. Densmore,Amrita Krishnan,Noopur Raje,Michael Bar,Thomas Martin,Robert L. Schlossman,Irene M. Ghobrial,Nikhil C. Munshi,Jacob P. Laubach,Jeff Allerton,Teru Hideshima,Kathleen Colson,Enrique Poradosu,L. Gardner,Peter Sportelli,Kenneth C. Anderson +21 more
TL;DR: Clinical data suggest that perifosine in combination with dexamethasone has activity in relapsed or relapsed/refractory multiple myeloma, and a phase III trial is underway comparing perifOSine-bortezomib plus dexamETHasone with bortzomib-dexameth asone in patients with relapsed / refractory MM previously treated with bortsomib.
Journal ArticleDOI
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
Johanna C. Bendell,John Nemunaitis,Sasha Vukelja,Christopher Hagenstad,Luis T. Campos,Robert C. Hermann,Peter Sportelli,L. Gardner,Donald A. Richards +8 more
TL;DR: P-CAP showed promising clinical activity compared with CAP in previously treated patients with mCRC, and a phase III trial is underway comparing P-CAP with CAP with placebo plus capecitabine in patients with refractory mC RC.
Journal ArticleDOI
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
Andrzej Jakubowiak,Andrzej Jakubowiak,Paul G. Richardson,Todd M. Zimmerman,Melissa Alsina,Jonathan L. Kaufman,Malathi Kandarpa,Stephanie J Kraftson,Stephanie J Kraftson,Charles W. Ross,Colleen K. Harvey,Teru Hideshima,Peter Sportelli,Enrique Poradosu,L. Gardner,Kathy Giusti,Kenneth C. Anderson +16 more
TL;DR: Perifosine–lenalidomide–dexamethasone was well tolerated and demonstrated encouraging clinical activity in relapsed and relapsed/refractory MM.
Journal ArticleDOI
Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.
Paul G. Richardson,Sagar Lonial,Andrzej Jakubowiak,Aparna Krishnan,Jeffrey L. Wolf,John J. Densmore,Seema Singhal,Irene M. Ghobrial,J. Stephenson,Jayesh Mehta,Kathleen Colson,Dixil Francis,Tara Kendall,N. Obadike,Kevin Sullivan,J. F. Martin,Teru Hideshima,L. Lai,Peter Sportelli,L. Gardner,Robert Birch,I. C. Henderson,KC Anderson +22 more
TL;DR: Perifosine as monotherapy has modest activity, but in combination with dex showed significant activity in pts with relapsed/refractory MM, achieving PR + MR in 38%, and/or stabilization of disease in 47% of evaluable pts to date.
Journal ArticleDOI
Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Johanna C. Bendell,Thomas Ervin,Neil Senzer,Donald A. Richards,Irfan Firdaus,A. Craig Lockhart,Allen Lee Cohn,Mansoor N. Saleh,L. Gardner,Peter Sportelli,Cathy Eng +10 more
TL;DR: A prospective, randomized, double-blind, placebo-controlled randomized phase III trial of P-CAP vs. CAP with a primary endpoint of overall survival (OS) in pts with refractory mCRC, which showed improvement in mTTP and mOS.